The purpose of this study is to learn about how the commonly used menopausal hormone therapies were prescribed and taken in practice. This is done by using healthcare database, to study the overall dangers and benefits of menopausal hormone therapies in real-world practice. This study will include subjects who were newly diagnosed menopausal symptoms between 2012 and 2019. They were all followed up for 12 months at least. The study included the below subjects who: * were aged 40-59 years * were diagnosed to have menopausal symptoms through some medical check-ups The data collected will be used to understand: * how the commonly used menopausal hormone therapies were prescribed and taken in practice * how patients took medication as prescribed by their doctors This might help to understand treatment trends of these therapies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Women Who Visited Hospitals for Menopausal Symptoms Distributed Per Year
Timeframe: Date of diagnosis of menopausal symptom during inpatient/outpatient hospital visit; retrospective data observed in this study for approximately 6 months
Number of Women With MHT Use Distributed Per Year
Timeframe: Index Date; retrospective data observed in this study for approximately 6 months
Number of Participants According to Each Type of Menopausal Symptoms Distributed Per Year
Timeframe: Date of diagnosis of menopausal symptom during inpatient/outpatient hospital visit; retrospective data observed in this study for approximately 6 months
Number of Participants According to Each Type of Menopausal Symptoms Per MHT
Timeframe: Index Date; retrospective data observed in this study for approximately 6 months
Number of Participants With Use of Any MHT According to Age Group
Timeframe: Index Date; retrospective data observed in this study for approximately 6 months
Number of Participants With MHT According to Type of Administration
Timeframe: Index Date; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Change in Treatment Regimen Change at Month 3
Timeframe: Month 3 post-index date; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Change in Treatment Regimen Change at Month 6
Timeframe: Month 6 post-index date; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Change in Treatment Regimen Change at Month 9
Timeframe: Month 9 post-index date; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Change in Treatment Regimen Change at Month 12
Timeframe: Month 12 post-index date; retrospective data observed in this study for approximately 6 months
Time to Discontinuation of MHT
Timeframe: During 2 year of follow up from index date; retrospective data observed in this study for approximately 6 months
Time to Switching of MHT
Timeframe: During 2 year of follow up from index date; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Treatment Persistence at Month 3 Post-index According to Treatment Type
Timeframe: Month 3 post-index; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Treatment Persistence at Month 6 Post-index According to Treatment Type
Timeframe: Month 6 post-index; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Treatment Persistence at Month 9 Post-index According to Treatment Type
Timeframe: Month 9 post-index; retrospective data observed in this study for approximately 6 months
Percentage of Participants With Treatment Persistence at Month 12 Post-index According to Treatment Type
Timeframe: Month 12 post-index; retrospective data observed in this study for approximately 6 months
Mean Treatment Adherence (%)
Timeframe: Index Date; retrospective data observed in this study for approximately 6 months